What is the optimal treatment regimen for carbapenem- and fluoroquinolone-resistant Pseudomonas aeruginosa infection?

Treatment of Carbapenem- and Fluoroquinolone-Resistant Pseudomonas aeruginosa

For severe infections caused by carbapenem- and fluoroquinolone-resistant Pseudomonas aeruginosa, use ceftolozane-tazobactam as first-line therapy if the isolate is susceptible in vitro, or alternatively cefiderocol, which maintains activity against most carbapenem resistance mechanisms. 1

Treatment Algorithm by Infection Severity

Severe Infections (Septic Shock, Pneumonia, Bloodstream Infection)

Preferred agents:

• Ceftolozane-tazobactam if active in vitro 1
• Cefiderocol as an alternative - this agent is particularly valuable because it remains stable against serine- and metallo-β-lactamases, is not affected by porin loss, and periplasmic levels are not impacted by upregulated efflux pumps 2

Combination therapy considerations:

• When treating severe infections with polymyxins, aminoglycosides, or fosfomycin, use two in vitro active drugs in combination 1
• No specific combination can be recommended over another, but the evidence supports using dual active agents rather than monotherapy when limited to older agents 1
• For ceftolozane-tazobactam or cefiderocol, there is insufficient evidence to recommend for or against combination therapy 1

Non-Severe or Low-Risk Infections

Use monotherapy with any in vitro active antibiotic, selected based on:

• Source of infection
• Individual patient factors
• Antibiotic stewardship principles 1

Specific Agent Considerations

Ceftazidime-Avibactam

• Has activity against some carbapenem-resistant strains, particularly those with KPC-type carbapenemases 3
• Monotherapy is as effective as combination therapy when the isolate is susceptible (RR for mortality 1.18,95% CI 0.88-1.58; no significant difference) 4
• Less reliable against Pseudomonas compared to ceftolozane-tazobactam for carbapenem resistance 1

Imipenem-Relebactam

• Insufficient evidence at this time for carbapenem-resistant Pseudomonas 1

Aminoglycosides

• Should be included in combination regimens for severe infections when other options are limited 1
• Monitor closely for nephrotoxicity and ototoxicity 5
• Avoid other nephrotoxic drugs in the combination 5
• Perform therapeutic drug monitoring when available, especially with high doses 5

Polymyxins (Colistin/Polymyxin B)

• Reserve for severe infections when newer agents are unavailable or inactive 3
• Use in combination with at least one other active agent 1
• Consider inhaled colistin as adjunctive therapy for pneumonia 6

Fosfomycin

• Only use intravenously in combination therapy when the isolate is confirmed susceptible or synergy testing demonstrates benefit 5
• Avoid in patients with hypernatremia, cardiac insufficiency, or renal insufficiency 5

Critical Pitfalls to Avoid

1. Do not use carbapenem-based combination therapy for carbapenem-resistant strains unless meropenem MIC is ≤8 mg/L and newer agents are unavailable 1

2. Do not use tigecycline for bloodstream infections or pneumonia caused by Pseudomonas - it has poor activity and outcomes 1

3. Piperacillin-tazobactam may have higher mortality in some carbapenem-resistant cases despite in vitro susceptibility to non-carbapenem β-lactams - use with caution 7

4. Verify susceptibility testing before initiating therapy - not all carbapenem-resistant Pseudomonas strains have the same resistance mechanisms, and cross-resistance patterns vary 8

Monitoring During Treatment

• Obtain susceptibility testing results and adjust therapy accordingly 8
• Monitor minimum inhibitory concentrations if treatment response is suboptimal 9
• Consider therapeutic drug monitoring for aminoglycosides and β-lactams in critically ill patients 5, 9
• Assess clinical response within 48-72 hours and modify regimen if no improvement

Key Prognostic Factors

Poor prognostic indicators requiring aggressive therapy include:

• Bloodstream infection (OR 1.97 for mortality) 7
• Septic shock (OR 3.3 for mortality) 7
• APACHE II score ≥14 7
• SOFA score ≥7 7
• Pitt bacteremia score ≥4 7